# Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA. 2 wave in Geneva, Switzerland 

This is a repository containing code used in the analysis used in the manuscript:

Zaballa, M.E., Perez-Saez, J., de Mestral, C., Pullen, N., Lamour, J., Turelli, P., Raclot, C., Baysson, H., Pennacchio, F., Villers, J. Duc, J., Richard V., Dumont R., Semaani C., Jutta A. Loizeau, Graindorge C., Lorthe E., Balavoine J-F, Pittet D., Schibler M., Vuilleumier N., Chappuis F., Kherad O.,ORCID Azman A.S., Posfay-Barbe K.M., Kaiser L., Trono D., Stringhini S., Guessous S. for the Specchio-COVID19 study group 2022. **Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA. 2 wave in Geneva, Switzerland**. medRxiv.  https://doi.org/10.1101/2022.07.27.22278126 

